INTRODUCTION
Prostate cancer has been shown to have a strong heritable component and to exhibit Mendelian inheritance patterns; however, the identification of highly penetrant genes accounting for hereditary prostate cancer has proven challenging. To our knowledge to date, there are a limited number of cancer predisposition genes that have been definitively shown to increase the risk of prostate cancer. In 2012, our laboratory identified a recurrent mutation in the homeobox protein Hox-B13 (HOXB13) gene on chromosome 17 through linkage analysis. 1 The HOXB13 G84E mutation typically occurs on a common haplotype consistent with a founder allele and accounts for approximately 5% of all cases of hereditary prostate cancer in men of European descent. 2 Some studies have found evidence that this G84E mutation increases the risk of other cancers and is observed more frequently in individuals with prostate cancer plus an additional primary cancer. [3] [4] [5] Prostate cancer is a potential phenotypic manifestation in individuals with germline mutations in homologous DNA damage repair (DDR) genes and individuals with Lynch syndrome (LS). Men in families with hereditary breast and ovarian cancer (HBOC) syndrome and who carry deleterious mutations in DDR genes, including BRCA2, have been observed to have an increased risk of prostate cancer and are more likely to have prostate cancer with a clinically aggressive phenotype. [6] [7] [8] Multiple recent studies of men with metastatic prostate cancer who were unselected for family history have shown that a significant minority of these individuals harbor pathogenic or likely pathogenic variants in DDR genes. [9] [10] [11] Studies also have found that prostate cancer is increased in individuals with LS, which classically presents as multiple individuals in a family presenting with 1 primary cancers including colorectal, small bowel, endometrial, and bladder/ureteral cancers and is due to germline mutations in mismatch repair genes. 12, 13 Known cancer susceptibility syndromes now number >100, although mutations in high-penetrance genes explain only a fraction of heritable cancers.
14 Common features of hereditary cancer syndromes include early age of onset, multiple affected generations, rare tumor types, and/ or multiple primary malignancies. However, hereditary cancers, similar to sporadic cancers, can be heterogeneous with regard to their presentation, pathology, and outcomes. Identifying individuals for genetic testing of cancer susceptibility genes is based primarily on family and personal cancer history with a goal of the prevention and early detection of cancers in these high-risk populations.
Multiple primary malignant neoplasms (MPMNs) (defined as tumors of different histology arising in distinct anatomic locations in a single individual) are relatively rare, reportedly comprising 6.3% of tumor registry cases. 15 MPMNs may be synchronous, occurring at the same time, or metachronous, occurring >6 months apart. 16 Individuals with certain cancer syndromes, such as Li-Fraumeni syndrome (LFS), are well known to carry a particularly high risk of developing MPMNs. For example, a study of unselected individuals with sarcoma demonstrated that sarcoma populations overall have a high incidence of pathogenic germline mutations, and that those germline carriers in the study were significantly more likely to have an MPMN phenotype. 17, 18 In addition, a retrospective study of individuals with multiple primary malignancies who were referred for clinical genetic testing found that 44 of 111 individuals (39.6%) carried a variant in 1 cancer predisposition genes, with DNA mismatch repair genes among the most frequently mutated. 19 Although the presence of certain constellations of MPMNs in a single individual is considered to be one indication for referral for genetic risk assessment, to the best of our knowledge the percentage of individuals with MPMNs who are referred for genetic assessment and the outcomes of clinical genetics referrals in these patients with multiple primary cancers has not been extensively described.
Given the evidence that rare deleterious mutations in cancer predisposition genes contribute to prostate cancer, we set out to determine the frequency of germline mutations in men with prostate cancer and at least 1 additional primary neoplasm. We hypothesized that by using a rigorous clinical definition including an MPMN phenotype and early-onset cancers, we would increase the likelihood of detecting those individuals with deleterious germline mutations, which are able to be passed on and confer a cancer risk to subsequent generations. We used a multigene panel approach, which provides the opportunity to sequence the coding regions of multiple genes simultaneously via next-generation sequencing.
MATERIALS AND METHODS

Patient Selection
Patients were selected from the University of Michigan's Prostate Cancer Genetics Project and Cancer Genetics Clinic registry. Both are approved by the local Institutional Review Board and obtained informed consent from each participant. The Prostate Cancer Genetics Project enrolls men with prostate cancer who have at least 1 living first-degree or second-degree relative with prostate cancer, and/or who were diagnosed with prostate cancer before age 55 years (>4000 consented individuals from 1792 families). The Cancer Genetics Clinic registry recruits patients with a personal or family history suggestive of hereditary cancer risk (approximately 5000 consented individuals from 3800 families). Initial queries of these 2 registries identified 414 men diagnosed with early-onset and/or familial prostate cancer who had been diagnosed with at least 1 additional primary malignancy (excluding nonmelanoma skin cancer). From these cases, we used the following criteria to further select patients for this study: 1) early age of onset of first malignancy (age 55 years); 2) diagnosed with rare cancers (eg, pancreatic cancer, testicular cancer, sarcoma, brain cancer, parathyroid cancer, or Hodgkin lymphoma); and/or 3) 3 primary malignancies diagnosed in a single individual. Each individual patient provided a cancer family history, which was pathologically confirmed when possible and was used to construct a 3-generation pedigree. Individuals who were known carriers of pathogenic germline mutations associated with hereditary cancer syndromes were excluded. Medical records pertaining to prostate cancer diagnoses were reviewed, and prostate cancers were categorized as clinically aggressive if they exhibited 1 the following features: a Gleason score >7, tumors classified as T3b or T4, a prediagnosis prostate-specific antigen (PSA) level >15 ng/mL, Gleason score of 7 and a prediagnosis PSA level >10 ng/mL, or N1 or M1 disease at the time of diagnosis.
The personal and family histories for each subject were reviewed by a certified genetic counselor to determine whether these were suggestive of a hereditary cancer syndrome and whether they met published criteria for clinical genetic testing (as defined by the National Comprehensive Cancer Network 
Gene Mutational Analysis
Gene mutation profiling was performed on DNA extracted from peripheral blood using the Qiagen GeneRead DNAseq Comprehensive Cancer Panel (CCP) (Qiagen Inc, Germantown, Maryland) consisting of multiplex polymerase chain reaction primer sets that amplify >95% of the exonic regions of a panel of genes, including genes associated with hereditary cancer syndromes with high and moderate penetrance as well as genes mutated in pathways involved in the carcinogenesis of prostate cancer and additional tumor types. The majority of samples (94 samples) were typed using version 2 of the Qiagen GeneRead DNAseq CCP, which included 160 genes. The remaining samples (8 samples) were typed using version 1 of the Qiagen GeneRead DNAseq CCP, which included 124 genes. A list of genes included in each panel is found in Supporting Information Table 1 . Sequencing was performed on an Illumina HiSeq (Illumina Inc, San Diego, California), and analysis of data was performed using the GeneRead Targeted Exon Enrichment Panel Data Analysis Portal (Qiagen Inc) (http://ngsdataanalysis.sabiosciences.com/ NGS2/). In addition, Sanger sequencing for the HOXB13 G84E allele was performed on 93 of 102 patients in this cohort for whom DNA was available, because HOXB13 was not included in either Qiagen gene panel.
Called variants were annotated with Annovar. 20 Deleterious, protein-truncating variants were identified, with putative functional importance preferentially given to stop/loss, frameshift insertions/deletions, and splice variants. All deleterious and missense variants were referenced for pathogenicity using the publically available databases ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) and Breast Cancer Information Core (BIC) (https:// research.nhgri.nih.gov/bic/), and established consensus guidelines. [21] [22] [23] Pathogenic and likely pathogenic variants were confirmed via Sanger sequencing.
Statistical Analysis
Clinicopathological characteristics including age at the time of diagnosis of the first primary tumor, age at the time of diagnosis of prostate cancer, and PSA level at the time of prostate cancer diagnosis were compared between pathogenic germline mutation carriers and noncarriers via a 2-sided Student t test. Gleason score, race, presence of 3 primary malignancies, whether or not the patient met NCCN criteria for genetic testing of any kind, and the presence of clinically aggressive prostate cancer were compared via the Fisher exact test. P values <.05 were deemed statistically significantly different.
RESULTS
Patients
A total of 102 men with prostate cancer, at least 1 additional primary cancer, and who met 1 of 3 additional inclusion criteria were selected for germline mutation profiling (Fig. 1) . The clinical characteristics of this study population are described in Table 1 . The mean age at the time of diagnosis of the first primary cancer was 51 years and the mean age at the time of prostate cancer diagnosis was 53 years. The majority of patients (76 of 102 patients) had 2 primary cancers, 22 had 3 primary cancers, and 4 patients had 4 primary cancers. Melanoma was the most common additional primary cancer (see Supporting Information Table 2 ). Greater than one-half of the men had prostate cancer of Gleason score 7, and 30% had clinically aggressive prostate cancer. Forty patients (39% of the current study cohort) met the criteria for clinical genetic testing of any syndrome based on review of personal and family histories, with the majority of patients (38 of 40 patients) meeting criteria for HBOC.
Germline Mutational Events
In total, >3500 variants were identified among the 102 individuals tested, including 2 nonsense, 7 frameshift, 5 in-frame coding insertions or deletions, and 525 missense variants. Eleven of the 102 men in the current study 
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(10.8%) harbored pathogenic or likely pathogenic mutations in cancer-predisposing genes. Eight men were found to harbor protein-truncating germline variants in 1 of 6 cancer predisposition genes: BRCA2 (3 cases), ataxia telangiectasia mutated (ATM; 2 cases), mutL homolog 1 (MLH1; 1 case), BRCA1 interacting protein C-terminal helicase 1 (BRIP1; 1 case), partner and localizer of BRCA2 (PALB2; 1 case), and fibroblast growth factor receptor 3 (FGFR3; 1 case), with 1 man harboring deleterious variants in both BRCA2 and MLH1 (Table 2 ). This patient had 3 primary malignancies (prostate cancer, kidney cancer, and bladder cancer). Review of the 525 missense mutations using ClinVar resulted in the identification of 2 likely pathogenic missense mutations in 2 men who had the same likely pathogenic missense variant in checkpoint kinase 2 (CHEK2). Additional sequencing of the HOXB13 prostate cancer-predisposing gene in 93 of 102 men identified 2 carriers of the known prostate cancer risk-associated G84E allele. One of these G84E carriers also harbored a pathogenic BRCA2 splice variant and had 3 primary malignancies: prostate cancer, liver cancer, and bladder cancer.
Men who harbored a germline mutation did not differ with respect to age of onset, family history, number of primary malignancies, or tumor phenotypes compared with those men who were not found to have a deleterious or pathogenic germline mutation from our panel of genes (see Supporting Information Table 3 ). Based on expert review of pedigrees using 2015 NCCN cancer genetics guidelines, only 4 of the 11 individuals with a pathogenic germline variant (36%) met the criteria for a hereditary cancer syndrome and would have qualified for clinical genetic testing based on their personal and/or family history. Three of these 4 individuals met the criteria for HBOC testing and harbored pathogenic variants in ATM, BRIP1, and CHEK2, respectively; the fourth individual met the criteria for HBOC and LS testing and harbored a pathogenic variant in both BRCA2 and MLH1. The aforementioned HOXB13 G84E allele and BRCA2 splice variant carrier with prostate cancer, liver cancer, and bladder cancer did not meet any criteria for testing.
DISCUSSION
We identified deleterious or likely pathogenic germline mutations in 10.8% of men with prostate cancer and 1 additional primary cancers. Protein-truncating variants were found in 6 genes (BRCA2, ATM, MLH1, BRIP1, PALB2, and FGFR3) and a likely pathogenic missense mutation was noted in 1 gene (CHEK2) from a multigene panel of 160 selected cancer genes, with the majority of these variants found in genes whose function is important for DDR. In addition, the prostate cancer risk-associated HOXB13 G84E allele, which recently has been shown to be associated with an increased risk of multiple cancers in a single individual, was found in 2 individuals with an MPMN phenotype. 4 The most frequently mutated gene in the current study was the HBOC gene, BRCA2. The majority of the individuals with pathogenic or likely pathogenic germline variants (7 of 11 patients) did not meet current criteria for clinical genetic testing and thus would Original Article likely not have been identified as being at risk of a hereditary cancer syndrome otherwise. In this pilot study, there was no difference noted with regard to carriers versus noncarriers in terms of prostate cancer metastatic disease, aggressiveness, or age of onset of prostate cancer. However, because the current study selected for early age of onset of malignancy as one of the inclusion criteria, it would be difficult to ascertain a difference with regard to the age of onset in carriers versus noncarriers from the current study population.
The prevalence of germline mutations in this selected population of men with prostate cancer is similar to the rates of 8% to 17% found in recent studies focusing on the identification of germline mutations in men with metastatic prostate cancer who were unselected for family history. [9] [10] [11] 24 Also similarly, the majority of deleterious variants in the current study were in DDR pathway genes. [9] [10] [11] 24 Unique to the current study population is that there was no statistical difference with regard to the presence of metastatic or aggressive disease noted in mutation carriers, suggesting that patients with multiple primary malignancies including prostate cancer may be at an increased risk of harboring deleterious germline mutations in DDR genes regardless of metastatic disease or Gleason score (Fig. 2) . Identifying these men with DDR mutations now is not only important for risk assessment but also for treatment given the sensitivity of DDR-deficient tumors to platinum-based chemotherapeutics and adenosine diphosphate (ADP) ribose polymerases (PARP) inhibitors. A phase 2 study of olaparib in previously treated patients with metastatic prostate cancer found that 6 of 50 patients harbored deleterious variants in the DDR-related genes ATM and BRCA2, with all 6 demonstrating a response to PARP inhibition. 9 In the era of targeted therapies, the early identification of a DDR germline mutation in men with prostate cancer and the MPMN phenotype could significantly alter the treatment course and outcomes for the multiple cancers in these patients.
The identification of a risk allele within an individual with cancer also has enormous impact for that patient's family members with regard to risk assessment, cancer screening, and cancer prevention. For example, men with BRCA2 germline mutations are known to be at an increased risk of prostate cancer, and typically demonstrate an earlier age of onset of disease and aggressive clinical phenotypes. 6, 7, 25, 26 These high-risk prostate cancer features have led to guideline recommendations for prostate cancer screening beginning at age 40 years in unaffected BRCA2 mutation carriers. The results of the current study also suggest that the use of multigene panel genetic tests may be particularly useful in this population given the varied tumor phenotypes, genes mutated, and the finding that a majority of the mutation carriers did not meet current NCCN guidelines for clinical genetic testing for hereditary cancer syndromes. For example, as seen in the pedigree shown in Figure 2 , a patient with prostate cancer and melanoma was found to harbor a deleterious BRCA2 mutation; however, this proband did not meet current clinical criteria for germline genetic testing. At the time of subsequent testing, this patient's unaffected brother also was found to have this same deleterious BRCA2 mutation. This exemplary finding will alter recommendations for cancer screening and treatment not only for the proband but also for his at-risk relatives, not only for prostate cancer but other HBOC-associated malignancies as well. Large-scale tumor sequencing via comprehensive panels focused on actionable mutations is quickly becoming ubiquitous at most comprehensive cancer centers, and the identification of germline variants of undetermined significance are an increasing concern. The results of the current study are in keeping with multiple recent studies of germline sequencing in patients with cancer demonstrating that germline aberrations in general are more frequent than previously believed and can be found in patients across all age groups and tumor types regardless of family history. 17, [27] [28] [29] [30] These studies highlight potential shortcomings in current clinical genetic testing practices, which rely primarily on constellations of specific personal and family cancer histories to determine whether a patient should pursue germline mutation testing. Additional parameters independent of family history, such as multiple primary cancers, early age of disease onset, and/or rare and/or aggressive histologies may be beneficial to add to the decision algorithm for germline testing in patients with prostate cancer.
Although the findings of the current study are novel, there are limitations, including the small sample size and the lack of paired somatic sequencing to better determine a pathogenic variant's impact on the phenotype of the tumor. We rely on the putative functional changes of a germline mutation to aid in determining its clinical pathogenic impact, which does not always align across tumor types. For example, a K3326X stop-gain variant in BRCA2 was found in 2 individuals in the current study; however, although this variant has been shown to increase the risk of developing breast and/or ovarian cancer, its pathogenicity in prostate cancer is less clear and is categorized as benign in ClinVar and thus was not included in our pathogenic carrier rate for the current study. 31 In addition, as with the majority of large-panel whole-exome sequencing studies, there is a high rate of variants of unknown significance, including missense variants of unknown clinical impact. Given the stringent criteria used in selecting for deleterious functional mutations, including restricting missense variants to only those referenced with supporting evidence as cancer-associated pathogenic or likely pathogenic in ClinVar, the pathogenic or likely pathogenic germline variant prevalence in the population in the current study may be underestimated. The reported prevalence also does not reflect any pathogenic variants harbored in genes not tested in this panel. It also should be noted that the vast majority of the selected patient population in the current study (approximately 90%) were negative for pathogenic or likely pathogenic mutations in the panel of cancer-associated genes; in addition, there were individuals who were discovered to have novel mutations or mutations in moderately penetrant genes. However, these individuals and their family members still may have an increased risk of prostate or other cancers and warrant longitudinal cancer screening. These findings highlight the potential clinical and ethical dilemmas regarding how to best inform patients and their families of cancer risk and highlight the necessity of a multidisciplinary approach to genetic screening and testing in patients with cancer that incorporates genetic counselors, physicians, molecular pathology, and psychosocial care for discussing, consenting, performing, and interpreting these genetic tests.
Quantifying and qualifying the prevalence and penetrance of pathogenic germline variants in unique subgroups of men with prostate cancer and multiple primary malignancies will provide a better understanding of the underlying molecular aberrations involved in the pathogenesis of different tumor types, allow for targeted therapeutic approaches, and better define high-risk groups of patients who would benefit from early screening and intervention. The results of the current study, along with those of other recent germline studies, have shown that certain clinical populations such as those with an MPMN phenotype, early-onset cancer, and/or metastatic/aggressive prostate cancer are enriched for germline variants and thus warrant consideration for genetic testing regardless of whether they meet current clinical criteria for hereditary cancer syndromes. However, health insurance does not typically cover genetic testing for patients outside of guideline criteria. It is particularly important for patients with prostate cancer and their families to identify heritable pathogenic variants that could prompt prostate screening in unaffected carriers, screening that otherwise is not currently recommended in the general US population. 32 Future larger studies to better define risk and outcomes in this population of men with prostate cancer and MPMNs who harbor deleterious germline variants is warranted.
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